Kobo Biotech's resolution plan by Beaufond Industries was approved, but the company reported a net loss of ₹5.23 crore for FY25, a widening from the previous year. Auditors noted significant data verification issues.
Kobo Biotech Ltd: Resolution Plan Approved Amidst Widened Losses and Audit Concerns
Kobo Biotech Limited has seen its resolution plan by Beaufond Industries Ltd approved by the NCLT Hyderabad Bench on May 11, 2026. However, the company reported a net loss of ₹5.23 crore for the financial year ended March 31, 2025. This marks a widening of losses from ₹4.93 crore in the previous fiscal year. Total income for FY25 stood at ₹0.08 crore, an increase from ₹0.02 crore in FY24.
Reader Takeaway: Approved resolution plan offers hope, but significant audit qualifications and non-operational status pose challenges.
What just happened
The National Company Law Tribunal (NCLT) Hyderabad Bench has approved the resolution plan for Kobo Biotech Ltd, submitted by Beaufond Industries Ltd. This approval comes as the company continues to operate under the Corporate Insolvency Resolution Process (CIRP). The financial results for the fiscal year 2024-25 show a net loss of ₹5.23 crore, a deterioration from the ₹4.93 crore loss recorded in FY24. Total income for FY25 was ₹0.08 crore, up from ₹0.02 crore in the prior year.
Why this matters
The approval of the resolution plan by Beaufond Industries is a crucial step towards potentially reviving Kobo Biotech. It signals a way out of the CIRP. However, the widening net loss and significant audit disclaimers highlight the deep-seated issues within the company that need to be addressed by the new management. Investors will be closely watching the implementation of this plan.
The backstory
Kobo Biotech has been under the Corporate Insolvency Resolution Process (CIRP) for some time, with its operations halted since 2016. The company's Solapur plant remains non-operational. Ms. Namrata Amol Randeri has been serving as the Resolution Professional, managing the company's affairs during this period.
What changes now
With the NCLT's approval, Beaufond Industries will take over the management and operations of Kobo Biotech, aiming to implement the approved resolution plan. This could lead to a restructuring of the company, its debt, and its operational framework. The previous board's powers remain suspended.
Risks to watch
Significant audit disclaimers, including the inability to verify employee benefit provisions and liabilities due to lack of documentation and non-cooperation from suspended management, pose a major risk. The company's status as a non-going concern for several years, with balance sheet figures largely carry-forwards, also presents challenges. Multiple instances of non-compliance in the Secretarial Audit Report, including failure to appoint Key Managerial Personnel and delayed listing fee payments, highlight governance issues.
Peer comparison
Kobo Biotech's situation is highly specific due to its CIRP status and operational halt. Direct peer comparisons are difficult as most listed companies operate actively. Companies undergoing insolvency proceedings typically have significantly different financial profiles and investor outlooks compared to healthy entities.
Context metrics (time-bound)
- Net Loss (FY25): ₹5.23 crore (widened from ₹4.93 crore in FY24)
- Total Income (FY25): ₹0.08 crore (increased from ₹0.02 crore in FY24)
- Resolution Plan Approval Date: May 11, 2026
- Operational Halt: Since 2016
What to track next
Investors should closely monitor stock exchange filings for updates on the implementation progress of Beaufond Industries' resolution plan. Any announcements regarding changes in management, operational restart plans, or restructuring of liabilities will be critical indicators of the company's future trajectory.